Treatment with mogalizumab (KW-0761), a defucosylated humanized anti-CCR4 antibody, showed promising efficacy and safety in patients with relapsed peripheral T cell lymphoma (PTCL), cutaneous T cell lymphoma (CTCL), and relapsed adult T cell leukemia or lymphoma (ATL) [113,114]. This evidence concerns the gene CCR4 and primary cutaneous T-cell non-Hodgkin lymphoma.